Recently Viewed
Clear AllValue Research Rating
Quality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
₹1,01,445 Cr
Revenue (TTM)
₹28,351 Cr
Net Profit (TTM)
₹4,546 Cr
ROE
18.3 %
ROCE
23.6 %
P/E Ratio
22.3
P/B Ratio
3
Industry P/E
27.85
EV/EBITDA
13.5
Div. Yield
1.3 %
Debt to Equity
0
Book Value
₹415.9
EPS
₹58.9
Face value
2
Shares outstanding
807,782,631
CFO
₹29,802.56 Cr
EBITDA
₹41,229.81 Cr
Net Profit
₹24,156.41 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Cipla
| -16.9 | -5.5 | -17.2 | -16.2 | 12.9 | 10.6 | 9.1 |
|
BSE Sensex
| -12.0 | -9.7 | -12.2 | -1.2 | 8.7 | 8.4 | 11.6 |
|
BSE Healthcare
| -2.6 | -1.7 | -3.7 | 3.2 | 25.2 | 15.5 | 10.7 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Cipla
| -1.2 | 22.2 | 15.8 | 14.0 | 14.2 | 72.3 | -8.6 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
|
BSE Healthcare
| -3.3 | 43.1 | 37.0 | -12.1 | 20.9 | 61.4 | -3.5 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Cipla
|
1,256.4 | 1,01,445.4 | 28,351.1 | 4,544.7 | 18.8 | 14.8 | 22.3 | 3.0 |
| 5,257.5 | 62,864.3 | 14,252.7 | 2,424.5 | 17.5 | 19 | 26.5 | 4.5 | |
| 1,291.4 | 75,004.7 | 33,181.9 | 3,513.2 | 15.4 | 10.4 | 21.5 | 2.1 | |
| 381.0 | 61,740.4 | 16,827.4 | 629.6 | 9.6 | -0.1 | 102.2 | 1.6 | |
| 1,298.9 | 1,08,417.3 | 34,682.2 | 5,508.7 | 17.6 | 16 | 19.5 | 2.9 | |
| 2,322.5 | 1,06,146.0 | 26,150.5 | 4,669.2 | 24.2 | 27 | 22.9 | 5.1 | |
| 2,000.0 | 82,555.3 | 13,914.1 | 1,792.3 | 17.8 | 12.6 | 46.4 | 5.3 | |
| 1,777.1 | 4,26,469.8 | 56,809.1 | 11,001.4 | 23.9 | 16.2 | 39.1 | 5.3 | |
| 4,270.2 | 1,44,440.1 | 12,742.0 | 2,272.0 | 26.3 | 28.8 | 63.6 | 15.9 | |
| 890.5 | 89,615.2 | 26,089.3 | 4,933.9 | 24.7 | 21 | 18.1 | 3.4 |
2 min read•By Mohammed Ekramul Haque
Challenge the equity-return assumption
6 min read•By Aarati Krishnan
FIIs Vs DIIs: Different strokes
3 min read•By Kumar Shankar Roy
2 min read•By Mohammed Ekramul Haque
2 min read•By Mohammed Ekramul Haque and Vikas Vardhan
Five stocks poised for take-off
1 min read•By Mohammed Ekramul Haque and Vikas Vardhan
Cipla Limited, together with its subsidiaries, manufactures, develops, and sells pharmaceutical products in India, the United States, South Africa, and internationally. The company operates through Pharmaceuticals and New ventures segments. It also... offers active pharmaceutical ingredients; and formulations in various therapeutic areas, such as MI, angina, heart failure, hypertension, arrhythmia, lipid abnormalities and diabetes, obesity, HIV, respiratory, urology, oncology, cardio-metabolism, child health, infectious diseases and critical care, hepatitis, women's health, ophthalmology, and neuro psychiatry. In addition, the company provides respiratory products, including inhalers and nasal sprays, as well as other respiratory products consists of injectables and biosimilars. Further, it offers Easylax and Easylax L, a liquid paraffin for constipation. Cipla Limited was incorporated in 1935 and is based in Mumbai, India. Read more
Incorporated
1935
Chairman
Y K Hamied
Managing Director
Umang Vohra
Group
Cipla
Headquarters
Mumbai, Maharashtra
Website
Our rating system has guided millions of investors in the past 20 years.
Annual Reports
The share price of Cipla Ltd is ₹1,256.40 (NSE) and ₹1,255.85 (BSE) as of 20-Mar-2026 IST. Cipla Ltd has given a return of 12.86% in the last 3 years.
The P/E ratio of Cipla Ltd is 22.31 times as on 20-Mar-2026, a 20 discount to its peers’ median range of 27.85 times.
The P/B ratio of Cipla Ltd is 3.02 times as on 20-Mar-2026, a 33 discount to its peers’ median range of 4.49 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
22.08
|
3.75
|
|
2024
|
29.28
|
4.53
|
|
2023
|
25.95
|
3.11
|
|
2022
|
32.65
|
3.95
|
|
2021
|
27.34
|
3.60
|
The 52-week high and low of Cipla Ltd are Rs 1,673.00 and Rs 1,235.40 as of 21-Mar-2026.
Cipla Ltd has a market capitalisation of ₹ 1,01,445 Cr as on 20-Mar-2026. As per SEBI classification, it is a Large Cap company.
Before investing in Cipla Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
₹17.20
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.